胸部肿瘤经皮穿刺活检中国专家共识(2020版)

2021-01-19 中国抗癌协会肿瘤介入专家委员会 中华医学杂志.2021.101(3):185-198.

病理穿刺活检是胸部肿瘤早期诊断和治疗的关键。随着影像导引设备不断更新和穿刺针的改进,经皮穿刺活检技术进步并得到广泛临床应用。精准医学时代,肿瘤基因组学推动了分子病理学发展,使得穿刺活检临床需求日益增大

中文标题:

胸部肿瘤经皮穿刺活检中国专家共识(2020版)

发布日期:

2021-01-19

简要介绍:

病理穿刺活检是胸部肿瘤早期诊断和治疗的关键。随着影像导引设备不断更新和穿刺针的改进,经皮穿刺活检技术进步并得到广泛临床应用。精准医学时代,肿瘤基因组学推动了分子病理学发展,使得穿刺活检临床需求日益增大。2017年5月17日,由中国抗癌协会肿瘤介入学专业委员会发起并启动胸部肿瘤经皮穿刺活检中国专家共识工作,共识于2018年发表于《中华医学杂志》和Thoracic Cancer,后续在中国抗癌协会继续教育部支持下,在不同地区、医院进行了10次规范化培训和推广工作,在指导并推动经皮穿刺活检术的临床实践中发挥了积极而重要作用。为进一步加强技术操作和临床管理的标准化和规范化,不断适应我国医疗领域发展需求,结合共识推广的应用体会及反馈建议,共识制定小组进一步更新文献证据和研究进展,完成了共识更新工作。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=胸部肿瘤经皮穿刺活检中国专家共识(2020版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=54b221c002061a82, title=胸部肿瘤经皮穿刺活检中国专家共识(2020版), enTitle=, guiderFrom=中华医学杂志.2021.101(3):185-198., authorId=0, author=, summary=病理穿刺活检是胸部肿瘤早期诊断和治疗的关键。随着影像导引设备不断更新和穿刺针的改进,经皮穿刺活检技术进步并得到广泛临床应用。精准医学时代,肿瘤基因组学推动了分子病理学发展,使得穿刺活检临床需求日益增大, cover=https://img.medsci.cn/2021215/1613319184872_2020535.jpg, journalId=0, articlesId=null, associationId=1562, associationName=中国抗癌协会肿瘤介入专家委员会, associationIntro=, copyright=0, guiderPublishedTime=Tue Jan 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>病理穿刺活检是胸部肿瘤早期诊断和治疗的关键。随着影像导引设备不断更新和穿刺针的改进,经皮穿刺活检技术进步并得到广泛临床应用。精准医学时代,肿瘤基因组学推动了分子病理学发展,使得穿刺活检临床需求日益增大。2017年5月17日,由中国抗癌协会肿瘤介入学专业委员会发起并启动胸部肿瘤经皮穿刺活检中国专家共识工作,共识于2018年发表于《中华医学杂志》和Thoracic Cancer,后续在中国抗癌协会继续教育部支持下,在不同地区、医院进行了10次规范化培训和推广工作,在指导并推动经皮穿刺活检术的临床实践中发挥了积极而重要作用。为进一步加强技术操作和临床管理的标准化和规范化,不断适应我国医疗领域发展需求,结合共识推广的应用体会及反馈建议,共识制定小组进一步更新文献证据和研究进展,完成了共识更新工作。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=43738, tagName=胸部肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=43738, guiderKeyword=胸部肿瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9135, appHits=229, showAppHits=0, pcHits=979, showPcHits=8906, likes=2, shares=17, comments=17, approvalStatus=1, publishedTime=Mon Feb 15 00:20:37 CST 2021, publishedTimeString=2021-01-19, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Feb 15 00:13:13 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 10:36:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=胸部肿瘤经皮穿刺活检中国专家共识(2020版).pdf)])
胸部肿瘤经皮穿刺活检中国专家共识(2020版).pdf
下载请点击:
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1217792, encodeId=998c121e792ac, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19488152558, createdName=ms9000001092967069, createdTime=Sun May 08 10:07:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198924, encodeId=9d0f119892484, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Mar 03 06:46:24 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084556, encodeId=4358108455651, content=好东西,急需, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a225177122, createdName=lengge, createdTime=Mon Dec 27 02:55:44 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078071, encodeId=394810e807146, content=好东西,保留了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7265310106, createdName=148861dfm10暂无昵称, createdTime=Wed Dec 08 11:28:42 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064608, encodeId=32f7106460859, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Thu Oct 28 10:14:03 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-05-08 ms9000001092967069

    好东西

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1217792, encodeId=998c121e792ac, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19488152558, createdName=ms9000001092967069, createdTime=Sun May 08 10:07:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198924, encodeId=9d0f119892484, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Mar 03 06:46:24 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084556, encodeId=4358108455651, content=好东西,急需, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a225177122, createdName=lengge, createdTime=Mon Dec 27 02:55:44 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078071, encodeId=394810e807146, content=好东西,保留了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7265310106, createdName=148861dfm10暂无昵称, createdTime=Wed Dec 08 11:28:42 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064608, encodeId=32f7106460859, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Thu Oct 28 10:14:03 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-03-03 未来将来

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1217792, encodeId=998c121e792ac, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19488152558, createdName=ms9000001092967069, createdTime=Sun May 08 10:07:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198924, encodeId=9d0f119892484, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Mar 03 06:46:24 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084556, encodeId=4358108455651, content=好东西,急需, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a225177122, createdName=lengge, createdTime=Mon Dec 27 02:55:44 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078071, encodeId=394810e807146, content=好东西,保留了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7265310106, createdName=148861dfm10暂无昵称, createdTime=Wed Dec 08 11:28:42 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064608, encodeId=32f7106460859, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Thu Oct 28 10:14:03 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-12-27 lengge

    好东西,急需

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1217792, encodeId=998c121e792ac, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19488152558, createdName=ms9000001092967069, createdTime=Sun May 08 10:07:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198924, encodeId=9d0f119892484, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Mar 03 06:46:24 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084556, encodeId=4358108455651, content=好东西,急需, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a225177122, createdName=lengge, createdTime=Mon Dec 27 02:55:44 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078071, encodeId=394810e807146, content=好东西,保留了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7265310106, createdName=148861dfm10暂无昵称, createdTime=Wed Dec 08 11:28:42 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064608, encodeId=32f7106460859, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Thu Oct 28 10:14:03 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-12-08 148861dfm10暂无昵称

    好东西,保留了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1217792, encodeId=998c121e792ac, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19488152558, createdName=ms9000001092967069, createdTime=Sun May 08 10:07:04 CST 2022, time=2022-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198924, encodeId=9d0f119892484, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Thu Mar 03 06:46:24 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084556, encodeId=4358108455651, content=好东西,急需, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a225177122, createdName=lengge, createdTime=Mon Dec 27 02:55:44 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078071, encodeId=394810e807146, content=好东西,保留了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7265310106, createdName=148861dfm10暂无昵称, createdTime=Wed Dec 08 11:28:42 CST 2021, time=2021-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064608, encodeId=32f7106460859, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ibELkPeBwZ9g2u0oYO5xpkQOvzftSwnchal614FcBGtxdyyyyiaVwhFUgampjItPgzI6xB4leHMZN4FegD0QX9icQ/132, createdBy=bcf65361120, createdName=ms6844877495285940, createdTime=Thu Oct 28 10:14:03 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-10-28 ms6844877495285940

    0

拓展阅读

胸部肿瘤经皮穿刺活检中国专家共识

中国抗癌协会肿瘤介入专家委员会 · 2018-06-19

2021 ESMO临床实践指南:恶性胸膜间皮瘤的诊断,治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2021-11-29

2021 专家共识:胸壁肿瘤切除与胸壁重建(英文)

中国肿瘤科相关专家小组(统称) · 2021-11-10

WHO胸部肿瘤分类(第5版)中胸膜、心包及胸腺肿瘤部分解读

同济大学附属上海市肺科医院病理科 · 2021-09-30